1
|
McRee SK, Bayer AL, Pietruska J, Tsichlis PN, Hinds PW. AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis. Cancers (Basel) 2023; 15:4958. [PMID: 37894325 PMCID: PMC10605002 DOI: 10.3390/cancers15204958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 10/02/2023] [Accepted: 10/10/2023] [Indexed: 10/29/2023] Open
Abstract
Despite recent advances in treatment, melanoma remains the deadliest form of skin cancer due to its highly metastatic nature. Melanomas harboring oncogenic BRAFV600E mutations combined with PTEN loss exhibit unrestrained PI3K/AKT signaling and increased invasiveness. However, the contribution of different AKT isoforms to melanoma initiation, progression, and metastasis has not been comprehensively explored, and questions remain about whether individual isoforms play distinct or redundant roles in each step. We investigate the contribution of individual AKT isoforms to melanoma initiation using a novel mouse model of AKT isoform-specific loss in a murine melanoma model, and we investigate tumor progression, maintenance, and metastasis among a panel of human metastatic melanoma cell lines using AKT isoform-specific knockdown studies. We elucidate that AKT2 is dispensable for primary tumor formation but promotes migration and invasion in vitro and metastatic seeding in vivo, whereas AKT1 is uniquely important for melanoma initiation and cell proliferation. We propose a mechanism whereby the inhibition of AKT2 impairs glycolysis and reduces an EMT-related gene expression signature in PTEN-null BRAF-mutant human melanoma cells to limit metastatic spread. Our data suggest that the elucidation of AKT2-specific functions in metastasis might inform therapeutic strategies to improve treatment options for melanoma patients.
Collapse
Affiliation(s)
- Siobhan K. McRee
- Program in Genetics, Graduate School of Biomedical Sciences, Tufts University, Boston, MA 02111, USA;
- Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA;
| | - Abraham L. Bayer
- Program in Immunology, Graduate School of Biomedical Sciences, Tufts University, Boston, MA 02111, USA;
- Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA
| | - Jodie Pietruska
- Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA;
| | - Philip N. Tsichlis
- Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210, USA;
| | - Philip W. Hinds
- Program in Genetics, Graduate School of Biomedical Sciences, Tufts University, Boston, MA 02111, USA;
- Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA;
| |
Collapse
|
2
|
McRee SK, Bayer AL, Pietruska J, Tsichlis PN, Hinds PW. AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.08.24.554685. [PMID: 37662310 PMCID: PMC10473698 DOI: 10.1101/2023.08.24.554685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
Despite recent advances in treatment, melanoma remains the deadliest form of skin cancer, due to its highly metastatic nature. Melanomas harboring oncogenic BRAF V600E mutations combined with PTEN loss exhibit unrestrained PI3K/AKT signaling and increased invasiveness. However, the contribution of different AKT isoforms to melanoma initiation, progression, and metastasis has not been comprehensively explored, and questions remain whether individual isoforms play distinct or redundant roles in each step. We investigate the contribution of individual AKT isoforms to melanoma initiation using a novel mouse model of AKT isoform-specific loss in a murine melanoma model, and investigate tumor progression, maintenance, and metastasis among a panel of human metastatic melanoma cell lines using AKT-isoform specific knockdown studies. We elucidate that AKT2 is dispensable for primary tumor formation but promotes migration and invasion in vitro and metastatic seeding in vivo , while AKT1 is uniquely important for melanoma initiation and cell proliferation. We propose a mechanism whereby inhibition of AKT2 impairs glycolysis and reduces an EMT-related gene expression signature in PTEN-null BRAF-mutant human melanoma cells to limit metastatic spread. Our data suggest that elucidation of AKT2-specific functions in metastasis could inform therapeutic strategies to improve treatment options for melanoma patients.
Collapse
|
3
|
Dinavahi SS, Chen YC, Punnath K, Berg A, Herlyn M, Foroutan M, Huntington ND, Robertson GP. Targeting WEE1/AKT restores p53-dependent NK cell activation to induce immune checkpoint blockade responses in 'cold' melanoma. Cancer Immunol Res 2022; 10:757-769. [PMID: 35439317 DOI: 10.1158/2326-6066.cir-21-0587] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 10/19/2021] [Accepted: 04/13/2022] [Indexed: 11/16/2022]
Abstract
Immunotherapy has revolutionized cancer treatment. Unfortunately, most tumor types do not respond to immunotherapy due to a lack of immune infiltration or 'cold' tumor microenvironment (TME), a contributing factor in treatment failure. Activation of the p53 pathway can increase apoptosis of cancer cells, leading to enhanced antigen presentation, and can stimulate natural killer (NK) cells through expression of stress ligands. Therefore, modulation of the p53 pathway in cancer cells with wildtype TP53 has the potential to enhance tumor immunogenicity to NK cells, produce an inflammatory TME, and ultimately lead to tumor regression. In this study, we report simultaneous targeting of the AKT/WEE1 pathways is a novel and tolerable approach to synergistically induce p53 activation to inhibit tumor development. This approach reduced the growth of melanoma cells and induced plasma membrane surface localization of the ER-resident protein calreticulin, an indicator of immunogenic cell death (ICD). Increase in ICD led to enhanced expression of stress ligands recognized by the activating NK cell receptor NKG2D, promoting tumor lysis. WEE1/AKT inhibition resulted in recruitment and activation of immune cells, including NK cells, in the TME, triggering an inflammatory cascade that transformed the 'cold' TME of B16F10 melanoma into a 'hot' TME that responded to anti-PD-1, resulting in complete regression of established tumors. These results suggest that AKT/WEE1 pathway inhibition is a potential approach to broaden the utility of class-leading anti-PD-1 therapies by enhancing p53-mediated, NK cell-dependent tumor inflammation and supports the translation of this novel approach to further improve response rates for metastatic melanoma.
Collapse
Affiliation(s)
| | - Yu-Chi Chen
- Penn State College of Medicine, Hershey, PA, United States
| | - Kishore Punnath
- Pennsylvania State University College of Medicine, Hershey, PA, United States
| | - Arthur Berg
- Pennsylvania State University College of Medicine, Hershey, PA, United States
| | | | | | | | - Gavin P Robertson
- Pennsylvania State University College of Medicine, Hershey, PA, United States
| |
Collapse
|
4
|
Targeting Protein Translation in Melanoma by Inhibiting EEF-2 Kinase Regulates Cholesterol Metabolism though SREBP2 to Inhibit Tumour Development. Int J Mol Sci 2022; 23:ijms23073481. [PMID: 35408842 PMCID: PMC8998919 DOI: 10.3390/ijms23073481] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 03/04/2022] [Accepted: 03/15/2022] [Indexed: 01/13/2023] Open
Abstract
Decreasing the levels of certain proteins has been shown to be important for controlling cancer but it is currently unknown whether proteins could potentially be targeted by the inhibiting of protein synthesis. Under this circumstance, targeting protein translation could preferentially affect certain pathways, which could then be of therapeutic advantage when treating cancer. In this report, eukaryotic elongation factor-2 kinase (EEF2K), which is involved in protein translation, was shown to regulate cholesterol metabolism. Targeting EEF2K inhibited key parts of the cholesterol pathway in cancer cells, which could be rescued by the addition of exogenous cholesterol, suggesting that it is a potentially important pathway modulated by targeting this process. Specifically, targeting EEF2K significantly suppressed tumour cell growth by blocking mRNA translation of the cholesterol biosynthesis transcription factor, sterol regulatory element-binding protein (SREBP) 2, and the proteins it regulates. The process could be rescued by the addition of LDL cholesterol taken into the cells via non-receptor-mediated-uptake, which negated the need for SREBP2 protein. Thus, the levels of SREBP2 needed for cholesterol metabolism in cancer cells are therapeutically vulnerable by targeting protein translation. This is the first report to suggest that targeting EEF2K can be used to modulate cholesterol metabolism to treat cancer.
Collapse
|
5
|
Inhibition of Axl Promotes the Therapeutic Effect of Targeted Inhibition of the PI3K/Akt Pathway in NRAS Mutant Melanoma Cells. JOURNAL OF ONCOLOGY 2022; 2022:2946929. [PMID: 35310910 PMCID: PMC8933087 DOI: 10.1155/2022/2946929] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Accepted: 02/01/2022] [Indexed: 12/30/2022]
Abstract
Melanoma is a malignant tumor produced by highly aggressive and metastatic melanocytes. NRAS mutation is a relatively common mutation in melanoma cells. Mitogen-activated protein kinase (MAPK) signaling pathway and the PI3K/Akt pathway in melanoma cells are relatively common signaling pathways. In this study, we investigated the effect of inhibition of Axl expression on the targeted inhibition of the PI3K/Akt pathway in NRAS-mutant melanoma cells. In this study, immunohistochemistry and western blot methods were used to detect the expression of Axl and Akt proteins in melanoma cells. Axl inhibitor was added, and it detected the inhibitory efficiency of Akt inhibitor in melanoma cells. Finally, a melanoma mouse model was established, and it detected the proliferation and apoptosis of mouse tumor cells induced by Axl inhibitor and Akt inhibitor. The results showed that Axl and Akt were highly expressed in NRAS-mutant melanoma cells, and stimulation of Axl expression could reduce the inhibitory effect of Akt inhibitor on melanoma cells. The addition of Axl inhibitor can synergistically promote the effect of Akt inhibitor, slow down the proliferation of tumor cells, and induce cell apoptosis. According to the experiment in this study, Axl inhibitor combined with Akt inhibitor has a stronger therapeutic effect on melanoma than Akt inhibitor alone.
Collapse
|
6
|
Kardos GR, Gowda R, Dinavahi SS, Kimball S, Robertson GP. Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery. Front Oncol 2020; 10:834. [PMID: 32637352 PMCID: PMC7317660 DOI: 10.3389/fonc.2020.00834] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Accepted: 04/28/2020] [Indexed: 12/15/2022] Open
Abstract
Increased protein synthesis is a key process in melanoma, which is regulated by the ALDH18A1 gene encoding pyrroline-5-carboxylate synthase (P5CS). P5CS is involved in proline biosynthesis and targeting ALDH18A1 has previously been shown to inhibit melanoma development by decreasing intracellular proline levels to increase the phosphorylation of eIF2α mediated by GCN2, which then impairs mRNA translation. Since there are no current inhibitors of P5CS, decreased eIF2α phosphorylation in melanoma was targeted using salubrinal (a specific inhibitor of eIF2α phosphatase enzymes). While salubrinal alone was ineffective, the combined use of salubrinal and 4E1RCat (a dual inhibitor of eIF4E:4E-BP1 and eIF4E:eIF4G interaction to prevent assembly of the eIF4F complex and inhibit cap-dependent translation) was found to be effective at decreasing protein synthesis, protein translation, and cell cycle progression to synergistically decrease melanoma cell viability and inhibited xenograft melanoma tumor development. The combination of these agents synergistically decreased melanoma cell viability while having minimal effect on normal cells. This is the first report demonstrating that it is possible to inhibit melanoma viability by targeting eIF2α signaling using salubrinal and 4E1RCat to disrupt assembly of the eIF4F complex.
Collapse
Affiliation(s)
- Gregory R Kardos
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,The Melanoma and Skin Cancer Center, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, PA, United States
| | - Raghavendra Gowda
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,The Melanoma and Skin Cancer Center, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, PA, United States
| | - Saketh Sriram Dinavahi
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,The Melanoma and Skin Cancer Center, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, PA, United States
| | - Scot Kimball
- Department of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, PA, United States
| | - Gavin P Robertson
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,The Melanoma and Skin Cancer Center, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,Department of Surgery, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,Department of Pathology, The Pennsylvania State University College of Medicine, Hershey, PA, United States.,Department of Dermatology, The Pennsylvania State University College of Medicine, Hershey, PA, United States
| |
Collapse
|
7
|
Dinavahi SS, Gowda R, Gowda K, Bazewicz CG, Chirasani VR, Battu MB, Berg A, Dokholyan NV, Amin S, Robertson GP. Development of a Novel Multi-Isoform ALDH Inhibitor Effective as an Antimelanoma Agent. Mol Cancer Ther 2020; 19:447-459. [PMID: 31754071 PMCID: PMC10763724 DOI: 10.1158/1535-7163.mct-19-0360] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 08/22/2019] [Accepted: 11/13/2019] [Indexed: 11/16/2022]
Abstract
The aldehyde dehydrogenases (ALDH) are a major family of detoxifying enzymes that contribute to cancer progression and therapy resistance. ALDH overexpression is associated with a poor prognosis in many cancer types. The use of multi-ALDH isoform or isoform-specific ALDH inhibitors as anticancer agents is currently hindered by the lack of viable candidates. Most multi-ALDH isoform inhibitors lack bioavailability and are nonspecific or toxic, whereas most isoform-specific inhibitors are not effective as monotherapy due to the overlapping functions of ALDH family members. The present study details the development of a novel, potent, multi-isoform ALDH inhibitor, called KS100. The rationale for drug development was that inhibition of multiple ALDH isoforms might be more efficacious for cancer compared with isoform-specific inhibition. Enzymatic IC50s of KS100 were 207, 1,410, and 240 nmol/L toward ALDH1A1, 2, and 3A1, respectively. Toxicity of KS100 was mitigated by development of a nanoliposomal formulation, called NanoKS100. NanoKS100 had a loading efficiency of approximately 69% and was stable long-term. NanoKS100 was 5-fold more selective for killing melanoma cells compared with normal human fibroblasts. NanoKS100 administered intravenously at a submaximal dose (3-fold lower) was effective at inhibiting xenografted melanoma tumor growth by approximately 65% without organ-related toxicity. Mechanistically, inhibition by KS100 significantly reduced total cellular ALDH activity to increase reactive oxygen species generation, lipid peroxidation, and accumulation of toxic aldehydes leading to apoptosis and autophagy. Collectively, these data suggest the successful preclinical development of a nontoxic, bioavailable, nanoliposomal formulation containing a novel multi-ALDH isoform inhibitor effective in the treatment of cancer.
Collapse
Affiliation(s)
- Saketh S Dinavahi
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- The Melanoma and Skin Cancer Center, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Raghavendra Gowda
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- The Melanoma and Skin Cancer Center, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- Foreman Foundation for Melanoma Research, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Krishne Gowda
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Christopher G Bazewicz
- The Melanoma and Skin Cancer Center, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- Department of Dermatology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Venkat R Chirasani
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Madhu Babu Battu
- Laboratory of Molecular Cell Biology, Centre for DNA Fingerprinting and Diagnostics, Uppal, Hyderabad, India
| | - Arthur Berg
- Department of Public Health Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Nikolay V Dokholyan
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Shantu Amin
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Gavin P Robertson
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
- The Melanoma and Skin Cancer Center, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- Foreman Foundation for Melanoma Research, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- Department of Dermatology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- Department of Pathology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
- Department of Surgery, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| |
Collapse
|
8
|
Gowda R, Dinavahi SS, Iyer S, Banerjee S, Neves RI, Pameijer CR, Robertson. GP. Nanoliposomal delivery of cytosolic phospholipase A 2 inhibitor arachidonyl trimethyl ketone for melanoma treatment. NANOMEDICINE : NANOTECHNOLOGY, BIOLOGY, AND MEDICINE 2018; 14:863-873. [PMID: 29317343 PMCID: PMC5899023 DOI: 10.1016/j.nano.2017.12.020] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Revised: 12/15/2017] [Accepted: 12/27/2017] [Indexed: 12/19/2022]
Abstract
Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A2 inhibitor, which can inhibit multiple key pathways responsible for the development of recurrent resistant disease. Free ATK is toxic, limiting its efficacy as a therapeutic agent. Hence, a novel nanoliposomal delivery system called NanoATK was developed, which loads 61.7% of the compound and was stable at 4oC for 12 weeks. The formulation decreased toxicity-enabling administration of higher doses, which was more effective at inhibiting melanoma cell growth compared to free-ATK. Mechanistically, NanoATK decreased cellular proliferation and triggered apoptosis to inhibit melanoma xenograft tumor growth without affecting animal weight. Functionally, it inhibited the cPLA2, AKT, and STAT3 pathways. Our results suggest the successful preclinical development of a unique nanoliposomal formulation containing ATK for the treatment of melanoma.
Collapse
Affiliation(s)
- Raghavendra Gowda
- Department of Pharmacology The Pennsylvania State University College of Medicine, Hershey, PA 17033,The Penn State Melanoma and Skin Cancer Center The Pennsylvania State University College of Medicine, Hershey, PA 17033,Penn State Melanoma Therapeutics Program The Pennsylvania State University College of Medicine, Hershey, PA 17033,Foreman Foundation for Melanoma Research The Pennsylvania State University College of Medicine, Hershey, PA 17033
| | - Saketh S. Dinavahi
- Department of Pharmacology The Pennsylvania State University College of Medicine, Hershey, PA 17033
| | - Soumya Iyer
- Department of Pharmacology The Pennsylvania State University College of Medicine, Hershey, PA 17033
| | - Shubhadeep Banerjee
- Department of Pharmacology The Pennsylvania State University College of Medicine, Hershey, PA 17033
| | - Rogerio I. Neves
- Department of Pharmacology The Pennsylvania State University College of Medicine, Hershey, PA 17033,Department of Dermatology and The Pennsylvania State University College of Medicine, Hershey, PA 17033 The Pennsylvania State University College of Medicine, Hershey, PA 17033,Department of Surgery The Pennsylvania State University College of Medicine, Hershey, PA 17033,The Penn State Melanoma and Skin Cancer Center The Pennsylvania State University College of Medicine, Hershey, PA 17033,Penn State Melanoma Therapeutics Program The Pennsylvania State University College of Medicine, Hershey, PA 17033,Foreman Foundation for Melanoma Research The Pennsylvania State University College of Medicine, Hershey, PA 17033
| | - Colette R. Pameijer
- Department of Surgery The Pennsylvania State University College of Medicine, Hershey, PA 17033,The Penn State Melanoma and Skin Cancer Center The Pennsylvania State University College of Medicine, Hershey, PA 17033,Penn State Melanoma Therapeutics Program The Pennsylvania State University College of Medicine, Hershey, PA 17033
| | - Gavin P. Robertson.
- Department of Pharmacology The Pennsylvania State University College of Medicine, Hershey, PA 17033,Department of Pathology The Pennsylvania State University College of Medicine, Hershey, PA 17033,Department of Dermatology and The Pennsylvania State University College of Medicine, Hershey, PA 17033 The Pennsylvania State University College of Medicine, Hershey, PA 17033,Department of Surgery The Pennsylvania State University College of Medicine, Hershey, PA 17033,The Penn State Melanoma and Skin Cancer Center The Pennsylvania State University College of Medicine, Hershey, PA 17033,Penn State Melanoma Therapeutics Program The Pennsylvania State University College of Medicine, Hershey, PA 17033,Foreman Foundation for Melanoma Research The Pennsylvania State University College of Medicine, Hershey, PA 17033
| |
Collapse
|
9
|
Dinavahi SS, Noory MA, Gowda R, Drabick JJ, Berg A, Neves RI, Robertson GP. Moving Synergistically Acting Drug Combinations to the Clinic by Comparing Sequential versus Simultaneous Drug Administrations. Mol Pharmacol 2017; 93:190-196. [PMID: 29242354 DOI: 10.1124/mol.117.110759] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Accepted: 12/12/2017] [Indexed: 01/21/2023] Open
Abstract
Drug combinations acting synergistically to kill cancer cells have become increasingly important in melanoma as an approach to manage the recurrent resistant disease. Protein kinase B (AKT) is a major target in this disease but its inhibitors are not effective clinically, which is a major concern. Targeting AKT in combination with WEE1 (mitotic inhibitor kinase) seems to have potential to make AKT-based therapeutics effective clinically. Since agents targeting AKT and WEE1 have been tested individually in the clinic, the quickest way to move the drug combination to patients would be to combine these agents sequentially, enabling the use of existing phase I clinical trial toxicity data. Therefore, a rapid preclinical approach is needed to evaluate whether simultaneous or sequential drug treatment has maximal therapeutic efficacy, which is based on a mechanistic rationale. To develop this approach, melanoma cell lines were treated with AKT inhibitor AZD5363 [4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide] and WEE1 inhibitor AZD1775 [2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one] using simultaneous and sequential dosing schedules. Simultaneous treatment synergistically reduced melanoma cell survival and tumor growth. In contrast, sequential treatment was antagonistic and had a minimal tumor inhibitory effect compared with individual agents. Mechanistically, simultaneous targeting of AKT and WEE1 enhanced deregulation of the cell cycle and DNA damage repair pathways by modulating transcription factors p53 and forkhead box M1, which was not observed with sequential treatment. Thus, this study identifies a rapid approach to assess the drug combinations with a mechanistic basis for selection, which suggests that combining AKT and WEE1 inhibitors is needed for maximal efficacy.
Collapse
Affiliation(s)
- Saketh S Dinavahi
- Division of Hematology-Oncology (J.J.D.); Departments of Pharmacology (S.S.D., M.A.N., R.G., R.I.N., G.P.R.), Medicine (J.J.D.), Public Health Sciences (A.B.), Dermatology (R.I.N., G.P.R.), Surgery (R.I.N., G.P.R.), and Pathology (G.P.R.); Melanoma and Skin Cancer Center (S.S.D., M.A.N., R.G., J.J.D., A.B., R.I.N., G.P.R.); Foreman Foundation for Melanoma Research (R.G., G.P.R.); and the Melanoma Therapeutics Program (R.G., R.I.N., G.P.R.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Mohammad A Noory
- Division of Hematology-Oncology (J.J.D.); Departments of Pharmacology (S.S.D., M.A.N., R.G., R.I.N., G.P.R.), Medicine (J.J.D.), Public Health Sciences (A.B.), Dermatology (R.I.N., G.P.R.), Surgery (R.I.N., G.P.R.), and Pathology (G.P.R.); Melanoma and Skin Cancer Center (S.S.D., M.A.N., R.G., J.J.D., A.B., R.I.N., G.P.R.); Foreman Foundation for Melanoma Research (R.G., G.P.R.); and the Melanoma Therapeutics Program (R.G., R.I.N., G.P.R.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Raghavendra Gowda
- Division of Hematology-Oncology (J.J.D.); Departments of Pharmacology (S.S.D., M.A.N., R.G., R.I.N., G.P.R.), Medicine (J.J.D.), Public Health Sciences (A.B.), Dermatology (R.I.N., G.P.R.), Surgery (R.I.N., G.P.R.), and Pathology (G.P.R.); Melanoma and Skin Cancer Center (S.S.D., M.A.N., R.G., J.J.D., A.B., R.I.N., G.P.R.); Foreman Foundation for Melanoma Research (R.G., G.P.R.); and the Melanoma Therapeutics Program (R.G., R.I.N., G.P.R.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Joseph J Drabick
- Division of Hematology-Oncology (J.J.D.); Departments of Pharmacology (S.S.D., M.A.N., R.G., R.I.N., G.P.R.), Medicine (J.J.D.), Public Health Sciences (A.B.), Dermatology (R.I.N., G.P.R.), Surgery (R.I.N., G.P.R.), and Pathology (G.P.R.); Melanoma and Skin Cancer Center (S.S.D., M.A.N., R.G., J.J.D., A.B., R.I.N., G.P.R.); Foreman Foundation for Melanoma Research (R.G., G.P.R.); and the Melanoma Therapeutics Program (R.G., R.I.N., G.P.R.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Arthur Berg
- Division of Hematology-Oncology (J.J.D.); Departments of Pharmacology (S.S.D., M.A.N., R.G., R.I.N., G.P.R.), Medicine (J.J.D.), Public Health Sciences (A.B.), Dermatology (R.I.N., G.P.R.), Surgery (R.I.N., G.P.R.), and Pathology (G.P.R.); Melanoma and Skin Cancer Center (S.S.D., M.A.N., R.G., J.J.D., A.B., R.I.N., G.P.R.); Foreman Foundation for Melanoma Research (R.G., G.P.R.); and the Melanoma Therapeutics Program (R.G., R.I.N., G.P.R.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Rogerio I Neves
- Division of Hematology-Oncology (J.J.D.); Departments of Pharmacology (S.S.D., M.A.N., R.G., R.I.N., G.P.R.), Medicine (J.J.D.), Public Health Sciences (A.B.), Dermatology (R.I.N., G.P.R.), Surgery (R.I.N., G.P.R.), and Pathology (G.P.R.); Melanoma and Skin Cancer Center (S.S.D., M.A.N., R.G., J.J.D., A.B., R.I.N., G.P.R.); Foreman Foundation for Melanoma Research (R.G., G.P.R.); and the Melanoma Therapeutics Program (R.G., R.I.N., G.P.R.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| | - Gavin P Robertson
- Division of Hematology-Oncology (J.J.D.); Departments of Pharmacology (S.S.D., M.A.N., R.G., R.I.N., G.P.R.), Medicine (J.J.D.), Public Health Sciences (A.B.), Dermatology (R.I.N., G.P.R.), Surgery (R.I.N., G.P.R.), and Pathology (G.P.R.); Melanoma and Skin Cancer Center (S.S.D., M.A.N., R.G., J.J.D., A.B., R.I.N., G.P.R.); Foreman Foundation for Melanoma Research (R.G., G.P.R.); and the Melanoma Therapeutics Program (R.G., R.I.N., G.P.R.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania
| |
Collapse
|